The Safety and Efficacy of DIOR Balloon in Coronary Bifurcation Lesions

Comparison of the Safety and Efficacy Between Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR) and Paclitaxel-Eluting Balloon (Bingo) in Coronary Bifurcation Lesions: A Prospective, Multicenter, Randomized, Controlled Trial (BEYOND II)

Sponsors

Lead Sponsor: CCRF Inc., Beijing, China

Source CCRF Inc., Beijing, China
Brief Summary

To evaluate the safety and effectiveness of paclitaxel-eluting coronary artery balloon dilation catheter (DIOR) in revascularization of coronary bifurcation lesions compared with paclitaxel-eluting balloon (Bingo), and to provide the clinical data for the formal application in China and for the approvement of China marketing.

Detailed Description

This is a prospective, multicenter, randomize, control and non-inferior study. 220 patients with bifurcation lesions will be randomized 1:1 to each group. after the main branch has been treated successfully, and if the side branch's stenosis is more than 70% and can be pre-dilated by POBA (plain old balloon angioplasty) successfully, then randomizing. the patients in the study group will be treated with paclitaxel-eluting coronary artery balloon dilatation catheter (DIOR), while those in the control group will be treated with paclitaxel-eluting balloon (Bingo). Clinical follow-up will be conducted at baseline, operation, hospital discharge, 1 month, 6 months, 9 months and 12 months after operation, and angiographic follow-up will be conducted at 9 months. The primary endpoint is late lumen loss (LLL) in the balloon dilatation coverage area of side branch of at 9 month after operation. The secondary endpoints include device success, clinical success, target lesion failure (TLF), target lesion revascularization (TLR), clinical composite endpoints and imaging endpoints. The information of adverse events, serious adverse events and device defects will be collected during the study.

Overall Status Not yet recruiting
Start Date 2019-03-01
Completion Date 2022-10-01
Primary Completion Date 2022-05-01
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
late lumen loss 9 months after operation
Secondary Outcome
Measure Time Frame
device success immediately post procedure
clinical success 1 month after operation
device oriented composite endpoints (DoCE) 1, 6, 9, 12 month after operation
patients oriented composite endpoints (PoCE) 1, 6, 9, 12 month after operation
all cause death 1, 6, 9, 12 month after operation
myocardial infarction (MI) 1, 6, 9, 12 month after operation
target lesion revasculation 1, 6, 9, 12 month after operation
target vessel revasculation 1, 6, 9, 12 month after operation
any coronary revasculation 1, 6, 9, 12 month after operation
thrombosis in the side branch lesion 1, 6, 9, 12 month after operation
Enrollment 220
Condition
Intervention

Intervention Type: Device

Intervention Name: Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)

Description: patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)

Arm Group Label: DIOR group

Intervention Type: Device

Intervention Name: Paclitaxel-Eluting Balloon (Bingo)

Description: patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)

Arm Group Label: Bingo group

Eligibility

Criteria:

Inclusion Criteria: Subjects that participate in this study must fulfill all the following criteria: General inclusion criteria: 1. Age from 18 to 80 years old, man or non-pregnant woman; 2. Subjects with stable or unstable angina, old myocardial infarction, or asymptomatic ischemic evidence with clinical diagnosis; 3. Subjects without contraindications of coronary artery bypass grafting (CABG); 4. Subjects must agree to the follow up of angiographic and clinical required in the study; 5. Subjects are able to understand the purpose of this study, provide an informed consent to show recognize to the study protocol. Angiographic inclusion criteria: 1. One or two bifurcation lesions, locate in different epicardial vessels, the bifurcation lesion in each epicardial vessel can not over 1; or 1 de nove coronary artery bifurcation can be included after 1 lesion of non-target vessel has been successfully treated by PCI (Percutaneous Coronary Intervention); 2. Residual diameter stenosis in main branch (MB) ≥ 70% (visually), or ≥ 50% simultaneously with clinical symptom, and the diameter stenosis in side branch (SB) ≥ 50% (visually); and the main branch's residual stenosis ≤ 20% with TIMI 3 flow post the stent placement, while the side branch diameter stenosis ≥ 70% post the MB stenting; 3. Fulfill the definition of truly bifurcation lesions by Medina type (1.1.1、1.0.1、0.1.1); 4. Diameter in side branch between ≥ 2.5 mm to ≤ 4.00 mm (visually) and lesion length ≤ 26 mm (visually); 5. Each side branch of the bifurcation lesion can be treated by only 1 study drug coated balloon (DCB) or control DCB, and the lesion shall be fully covered by the DCB ( the distal end of the balloon shall exceed the lesion at least 1 mm). Exclusion Criteria: If subjects fulfill any of below criteria, this subject shall be exclude from this study. General exclusion criteria: 1. Pregnant or lactating women 2. Any newly myocardial infarction onset within 1 week or, the myocardial enzyme of CK (Creatine Kinase) or CK-MB does not return to normal level after any myocardial infarction; 3. Cardiogenic shock; 4. Severe chronic heart failure, NYHA (New York Heart Association) ≥ grade III, or left ventricular ejection fraction < 35% (accessed by echocardiography or left ventricular angiography) 5. Patients with renal insufficiency (estimated glomerular filtration rate < 30ml/min/1.73m2 calculated by MRDR (Modification of Diet in Renal Disease) formula or subject is receiving renal dialysis) 6. Having a history of hemorrhagic diseases such as cerebral hemorrhage, gastrointestinal hemorrhage; stroke occurring or any situation occurring that may lead to prolongation of anticoagulation therapy within 6 months before operation; 7. History of coronary or peripheral vascular interventional therapy within 12 months before hospitalized. 8. Patients are allergic or contraindicate to contrast agent, paclitaxel, heparin, antiplatelet and anticoagulant drug; 9. The Subjects have other serious diseases and the expected survival is less than 12 months; 10. Investigators determine the subjects' compliance is poor, cannot complete the study as required; Angiographic exclusion criteria 1. Main branch lesion or non-target lesion(s) located in left main; 2. Main branch lesion or non-target lesion(s) is triple vessel lesion, all need to be treated; 3. Side branch lesion is triple bifurcation or multiple bifurcation; 4. Main branch lesion located within 3 mm of the origin of the LAD (Left Anterior Descending), LCX (Left Circumflex Branch) or RCA (Right Coronary Arter); 5. Side branch target lesion is diffusion lesion and length > 26mm; or a ≥90% stenosis lesion is found near the SB lesion within 5 mm; 6. Side branch as the target vessel has received any interventional treatment; 7. Side branch as the target lesion or target vessel involve in aneurysm; 8. The lesion in side branch or main branch is total occlusive lesions, with TIMI blood flow of grade 0; 9. Side branch target lesion is moderate or heavy calcified or target vessel excessive tortuosity, which is unfavorable for interventional treatment anatomically; 10. Subject's blood pressure is too low to be injected with nitroglycerin ≥ 100 ug, this subject can not be included in the study; 11. Side branch target lesion can not reach the following outcomes, after the completely balloon pre-dilatation: 1) Residual stenosis (DS %) is ≤50% (visually); 2) TIMI Grade-3 flow ((visually); 3) No angiographic complications (e.g., no-reflow, distal embolization, side branch closure) 4) No dissections NHLBI grade C-F;

Gender:

All

Minimum Age:

18 Years

Maximum Age:

80 Years

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Yaling Han, professor Principal Investigator General Hospital of Northern Theater Command
Overall Contact Contact information is only displayed when the study is recruiting subjects.
Location
Facility: Contact:
Daqing Oil General Hospital | Daqing, Heilongjiang, China Hui Li, professor 86-0459-5805310
Wuhan Asian Heart Hospital | Wuhan, Hubei, China Xi Su, professor 86-027-65796888 [email protected]
Nanjing First Hospital | Nanjing, Jiangsu, China Saoliang Chen, professor 86-025-52271351 [email protected]
First Bethune Hospital of Jilin University | Changchun, Jilin, China
The Second Hospital of Dalian University | Dalian, Liaonin, China
General Hospital of Northern Theater Command | Shengyang, Liaonin, China Han Yaling, professor 86-024-28851120 [email protected]
The First Hospital of China Medical University | Shengyang, Liaonin, China Yingxian Sun 86-024-83283166
First Affiliated Hospital of Kunming Medical University | Kunming, Yunnan, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China Guosheng Fu, professor 86-0571-86090073 [email protected]
The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China Wang jian'an, professor 86-0571-87783777 [email protected]
Beijing Anzhen Hospital Capital Medical University | Beijing, China
Shanghai East Hospital, | Shanghai, China Qi Zhang, professor 86-021-38804518
Tianjin Chest Hospital | Tianjin, China Hongliang Cong, professor 86-022-88185003 [email protected]
Location Countries

China

Verification Date

2019-01-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Number Of Arms 2
Arm Group

Label: DIOR group

Type: Experimental

Description: in this group, patients will be treated with Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)

Label: Bingo group

Type: Active Comparator

Description: in this group, patients will be treated with Paclitaxel-Eluting Balloon (Bingo)

Acronym BEYOND-II
Patient Data Undecided
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Percutaneous Coronary Intervention

Clinical Trials on Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)